1-year investment window? Check this out

1/6
The guide is here

The guide is here

For investors, the upcoming national elections are a force to reckon with. The Interim Budget has already given its cues.

Market participants are closely tracking the RBI policy trajectory, the first under the new Governor Shaktikanta Das.

There are other variables at play, too.

So, which stocks can come to your rescue with all these uncertainties around? Edelweiss Securities has stuck its neck out. We bring you its calls.

2/6
Getty Images
​ Titan Company| Buy| Target price: Rs 1,182

​ Titan Company| Buy| Target price: Rs 1,182

Investment rationale: Titan Company’s third-quarter revenue, adjusted EBITDA and PAT growth of 34.3 per cent, 47.1 per cent and 35 per cent YoY, respectively, surpassed Streets’ estimates. Titan’s jewellery division delivered robust growth backed by studded and retail, watches sustained healthy sales growth and eyewear division’s renewed strategy seems to be reaping benefits. FY20 looks promising looking at the number of wedding season days. Titan may extend its growth run, led by market share gains, rising share of studded jewellery, new launches and retail expansion. Margin expansion levers such as higher share of studded (jewellery), in-house frame manufacturing (eyewear), cost optimisation and operating leverage are in place.

3/6
BCCL
State Bank of India| Buy| Target price: Rs 35

State Bank of India| Buy| Target price: Rs 35

Investment rationale: State Bank of India (SBI), after muted earnings since the past many quarters, posted a respectable PAT in December quarter of Rs 3,950 crore with improved prospects. The company clocked steady improvement in operating metrics and is better positioned to capture emerging opportunities amidst slackened competition. Further, value in non-banking subsidiaries will be more stable and scalable.

4/6
Reuters

Sample Newsletter

​ Dabur| Buy| Target price: Rs 535

​ Dabur| Buy| Target price: Rs 535

Investment rationale: Dabur India’s third-quarter results were in line with our estimates with revenue, EBITDA and PAT growing 11.8 per cent, 10.4 per cent and 10.3 per cent YoY, respectively. The third quarter growth by category is well diversified and well performing categories are making further inroads. Rural growth was 400bps higher than Urban growth. The brokerage expects volume recovery to not only sustain but improve also, aided by the expansion of the herbal market, premiumisation, innovative launches and a potential uptick in rural spending.

5/6
ETMarkets.com
​ Dr. Reddy’s Laboratories| Buy| Target price: Rs 3,450

​ Dr. Reddy’s Laboratories| Buy| Target price: Rs 3,450

Dr. Reddy’s Laboratories| Buy| Target price: Rs 3,450
Investment rationale: Dr. Reddy’s Laboratories’ strong third-quarter numbers show that the company is on track to achieve healthy earnings growth. Domestic business grew 10 per cent YoY on new products launches and is tracking in-line with guidance. The company’s promising complex generics pipeline, strong earnings revival and compelling valuations (15.7x FY20E EPS) make it a prime re-rating candidate.

6/6
Getty Images
 Bharti Airtel| Buy| Target price: Rs 396

Bharti Airtel| Buy| Target price: Rs 396

Investment rationale: Bharti Airtel’s third-quarter numbers were broadly in line with Street’s estimates. High network investments will help Bharti sustain 4G subscriber addition momentum, which is crucial for maintaining revenue market share. The brokerage expects Arpu to start improving over the next 12 months as operators focus on RoCE over market share.

 

[“source=economictimes.indiatimes”]